AP NEWS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

BeiGene Announces Clinical Data on Tislelizumab and Zanubrutinib to be Presented at the 24th Congress of the European Hematology Association

May 16, 2019

CAMBRIDGE, Mass. and BEIJING, China, May 16, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced data presentations on its investigational anti-PD-1 antibody tislelizumab and its investigational BTK inhibitor zanubrutinib from four posters at the 24th Congress of the European Hematology Association (EHA), taking place June 13-16, 2019 in Amsterdam.

Poster Presentations:

Title: Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: updated follow-up efficacy and safety results from a Phase 2 study Abstract Code: PF469 Session Title: Hodgkin lymphoma – Clinical Date: Friday, June 14 Time: 17:30 – 19:00 (CEST) Lead Author: Yuqin Song, M.D., Ph.D.

Title: Major responses in MYD88 wildtype (MYD88WT) Waldenström Macroglobulinemia (WM) patients treated with Bruton Tyrosine Kinase (BTK) inhibitor zanubrutinib (BGB-3111) Abstract Code: PF487 Session Title: Indolent and mantle-cell non-Hodgkin lymphoma – Clinical Date: Friday, June 14 Time: 17:30 – 19:00 (CEST) Lead Author: Meletios A. Dimopoulos, M.D.

Updated safety and efficacy data in a Phase 1/2 trial of patients with Waldenström Title: Macroglobulinaemia (WM) treated with the Bruton Tyrosine Kinase (BTK) inhibitor zanubrutinib (BGB-3111) Abstract Code: PF481 Session Title: Indolent and mantle-cell non-Hodgkin lymphoma – Clinical Date: Friday, June 14 Time: 17:30 – 19:00 (CEST) Lead Author: Judith Trotman, MBChB, FRACP, FRCPA

Title: Pooled analysis of safety data from monotherapy studies of the Bruton Tyrosine Kinase (BTK) inhibitor, zanubrutinib (BGB-3111), in B-cell malignancies Abstract Code: PS1159 Session Title: Chronic lymphocytic leukemia and related disorders – Clinical Date: Saturday, June 15 Time: 17:30 – 19:00 (CEST) Lead Author: Constantine S. Tam, M.D.

About BeiGene

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 2,400 employees in China, the United States, Australia and Europe, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin-bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.i

Investor Contact Media ContactCraig West Liza Heapes+1 857-302-5189 +1 857-302-5663ir@beigene.com media@beigene.com

i ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of Celgene Corporation